TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07047612: A Phase II/III Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive Design, Multi-center Study to Evaluate the Efficacy and Safety of ICP-332 in Subjects With Non-segmental Vitiligo

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. · Phase: PHASE2/PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 603 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,948,964

Rescue Site Savings

+$3,934,500

Unlock Full NCT07047612 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07047612 Rescue Dossier →